Virax Biolabs Group Limited (VRAX) shares are down today following the announcement of a $5 million registered direct offering. The company plans to use the proceeds for working capital and general corporate purposes. While the stock has seen significant gains recently, its high RSI suggests it might be overbought.
Virax Biolabs Group Limited (VRAX) shares surged on Monday as investors seek exposure to companies developing treatments for mpox, following the World Health Organization’s declaration of a global health emergency last week. The company’s focus on diagnostics and a potential T-Cell Test for mpox has attracted investor attention. This article explores how to invest in Virax Biolabs and provides insights into the current market dynamics.
